EXACT Sciences Corp. Stock Rating Reaffirmed by Maxim Group (EXAS)
EXACT Sciences Corp. (NASDAQ:EXAS)‘s stock had its “sell” rating restated by stock analysts at Maxim Group in a report issued on Tuesday, StockRatingsNetwork.com reports.
Shares of EXACT Sciences Corp. (NASDAQ:EXAS) traded down 1.30% during mid-day trading on Tuesday, hitting $10.97. The stock had a trading volume of 610,891 shares. EXACT Sciences Corp. has a one year low of $6.93 and a one year high of $14.70. The stock’s 50-day moving average is $12.54 and its 200-day moving average is $11.57. The company’s market cap is $775.6 million.
EXACT Sciences Corp. (NASDAQ:EXAS) last announced its earnings results on Tuesday, October 29th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $1.02 million. During the same quarter last year, the company posted ($0.21) earnings per share. EXACT Sciences Corp.’s revenue was up .0% compared to the same quarter last year. On average, analysts predict that EXACT Sciences Corp. will post $-0.74 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on EXAS. Analysts at Wedbush upgraded shares of EXACT Sciences Corp. from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, October 16th. Separately, analysts at Summer Street initiated coverage on shares of EXACT Sciences Corp. in a research note to investors on Monday, September 16th. They set a “buy” rating on the stock. Finally, analysts at Benchmark Co. initiated coverage on shares of EXACT Sciences Corp. in a research note to investors on Tuesday, September 10th. They set a “speculative buy” rating and a $20.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. EXACT Sciences Corp. currently has an average rating of “Buy” and an average price target of $17.18.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.